Terms: = Prostate cancer AND CTLA4, ALPS5, CD, CD152, CELIAC3, CTLA-4, GRD4, GSE, IDDM12 AND Treatment
267 results:
1. Expression of stem cell markers as predictors of therapeutic response in metastatic prostate cancer patients.
Nandagopal S; Choudhary G; Sankanagoudar S; Banerjee M; Elhence P; Jena R; Selvi MK; Shukla KK
Urol Oncol; 2024 Mar; 42(3):68.e21-68.e31. PubMed ID: 38278632
[TBL] [Abstract] [Full Text] [Related]
2. Immune Modulation with RANKL Blockade through Denosumab treatment in Patients with cancer.
Chang H; Marquez J; Chen BK; Kim DM; Cheng ML; Liu EV; Yang H; Zhang L; Sinha M; Cheung A; Kwek SS; Chow ED; Bridge M; Aggarwal RR; Friedlander TW; Small EJ; Anderson M; Fong L
Cancer Immunol Res; 2024 Apr; 12(4):453-461. PubMed ID: 38276989
[TBL] [Abstract] [Full Text] [Related]
3. Efficacy and safety of immune checkpoint inhibitors for patients with prostate cancer: a systematic review and meta-analysis.
Noori M; Azizi S; Mahjoubfar A; Abbasi Varaki F; Fayyaz F; Mousavian AH; Bashash D; Kardoust Parizi M; Kasaeian A
Front Immunol; 2023; 14():1181051. PubMed ID: 38022569
[TBL] [Abstract] [Full Text] [Related]
4. M2pep-Modified Cyclodextrin-siRNA Nanoparticles Modulate the Immunosuppressive Tumor Microenvironment for prostate cancer Therapy.
Sun Y; Cronin MF; Mendonça MCP; Guo J; O'Driscoll CM
Mol Pharm; 2023 Nov; 20(11):5921-5936. PubMed ID: 37874541
[TBL] [Abstract] [Full Text] [Related]
5. The Prognosis-Predictive and Immunoregulatory Role of SUMOylation Related Genes: Potential Novel Targets in prostate cancer treatment.
Sun JX; An Y; Xiang JC; Xu JZ; Hu J; Wang SG; Xia QD
Int J Mol Sci; 2023 Sep; 24(17):. PubMed ID: 37686409
[TBL] [Abstract] [Full Text] [Related]
6. Cisplatin binding to angiogenin protein: new molecular pathways and targets for the drug's anticancer activity.
Ferraro G; Sanfilippo V; Chiaverini L; Satriano C; Marzo T; Merlino A; La Mendola D
Dalton Trans; 2023 Jul; 52(26):9058-9067. PubMed ID: 37337706
[TBL] [Abstract] [Full Text] [Related]
7. Targeting prostate cancer with docetaxel-loaded peptide 563-conjugated PEtOx-co-PEI
Nezir AE; Bolat ZB; Ozturk N; Kocak P; Zemheri E; Gulyuz S; Ozkose UU; Yilmaz O; Vural I; Bozkır A; Sahin F; Telci D
Amino Acids; 2023 Aug; 55(8):1023-1037. PubMed ID: 37318626
[TBL] [Abstract] [Full Text] [Related]
8. Proapoptotic effect of nonthermal pulsed ultrasound on prostate cancer cells in a nude mouse model.
Maeda K; Shigemura K; Hayashi F; Kan Y; Hiraoka A; Yamaguchi A; Ueda M; Yang YM; Maeshige N; Ooya T; Nakano Y; Fujisawa M
Prostate; 2023 Sep; 83(12):1217-1226. PubMed ID: 37221965
[TBL] [Abstract] [Full Text] [Related]
9. Investigation on the mechanisms by which the herbal remedies induce anti-prostate cancer activity: uncovering the most practical natural compound.
Poustforoosh A; Faramarz S; Negahdaripour M; Tüzün B; Hashemipour H
J Biomol Struct Dyn; 2024 Apr; 42(7):3349-3362. PubMed ID: 37194430
[TBL] [Abstract] [Full Text] [Related]
10. Integrated analysis of single-cell and bulk RNA sequencing identifies a signature based on macrophage marker genes involved in prostate cancer prognosis and treatment responsiveness.
Li X; Zheng C; Xue X; Wu J; Li F; Song D; Li X
Funct Integr Genomics; 2023 Apr; 23(2):115. PubMed ID: 37010617
[TBL] [Abstract] [Full Text] [Related]
11. Nitazoxanide inhibits acetylated KLF5-induced bone metastasis by modulating KLF5 function in prostate cancer.
Huang Q; Liu M; Zhang D; Lin BB; Fu X; Zhang Z; Zhang B; Dong JT
BMC Med; 2023 Feb; 21(1):68. PubMed ID: 36810084
[TBL] [Abstract] [Full Text] [Related]
12. Tumor-derived OBP2A promotes prostate cancer castration resistance.
Jeong JH; Zhong S; Li F; Huang C; Chen X; Liu Q; Peng S; Park H; Lee YM; Dhillon J; Luo JL
J Exp Med; 2023 Mar; 220(3):. PubMed ID: 36547668
[TBL] [Abstract] [Full Text] [Related]
13. Knowledge mapping and current trends of immunotherapy for prostate cancer: A bibliometric study.
Zhong W; Shen Z; Wu Y; Mao X; Kong J; Wu W
Front Immunol; 2022; 13():1014981. PubMed ID: 36389756
[TBL] [Abstract] [Full Text] [Related]
14. Identification of LAT/ZAP70 characterized immune subtypes of prostate cancer.
Yu J; Gao W; Gao S; Wen S; Zhao Y; Shang Z; Wang Y; Niu Y
World J Urol; 2022 Nov; 40(11):2817-2824. PubMed ID: 36205741
[TBL] [Abstract] [Full Text] [Related]
15. Multi-institution model (big model) versus single-institution model of knowledge-based volumetric modulated arc therapy (VMAT) planning for prostate cancer.
Fukunaga JI; Tamura M; Ueda Y; Kamima T; Shimizu Y; Muraki Y; Nakamatsu K; Monzen H
Sci Rep; 2022 Sep; 12(1):15282. PubMed ID: 36088382
[TBL] [Abstract] [Full Text] [Related]
16. Cyclodextrin-based supramolecular nanoparticles break the redox balance in chemodynamic therapy-enhanced chemotherapy.
Xing C; Chen H; Guan Y; Zhang S; Tong T; Ding N; Luo T; Kang Y; Pang J
J Colloid Interface Sci; 2022 Dec; 628(Pt B):864-876. PubMed ID: 36029600
[TBL] [Abstract] [Full Text] [Related]
17. Antitumor efficacy of
Potluri HK; Ferreira CA; Grudzinski J; Massey C; Aluicio-Sarduy E; Engle JW; Kwon O; Marsh IR; Bednarz BP; Hernandez R; Weichert JP; McNeel DG
J Immunother Cancer; 2022 Aug; 10(8):. PubMed ID: 36002185
[TBL] [Abstract] [Full Text] [Related]
18. Neoadjuvant immunotherapy across cancers: meeting report from the Immunotherapy Bridge-December 1st-2nd, 2021.
Burton EM; Amaria RN; Cascone T; Chalabi M; Gross ND; Mittendorf EA; Scolyer RA; Sharma P; Ascierto PA
J Transl Med; 2022 Jun; 20(1):271. PubMed ID: 35706041
[TBL] [Abstract] [Full Text] [Related]
19. Characterization of a Pyroptosis-Related Signature for Prognosis Prediction and Immune Microenvironment Infiltration in prostate cancer.
Zhang G; Luo Y; Dong W; Zhong W
Comput Math Methods Med; 2022; 2022():8233840. PubMed ID: 35516457
[TBL] [Abstract] [Full Text] [Related]
20. Use of immunotherapy in clinical management of genitourinary cancers - a review.
Mar N; Uchio E; Kalebasty AR
Cancer Treat Res Commun; 2022; 31():100564. PubMed ID: 35472699
[TBL] [Abstract] [Full Text] [Related]
[Next]
